The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis. [PDF]
Drugs, 2022 Edwards BD, Field SK.
europepmc +1 more source
In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. [PDF]
Antimicrob Agents Chemother, 2021 Kim DH, Kim SY, Koh WJ, Jhun BW.
europepmc +1 more source
Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus. [PDF]
Microbiol Spectr, 2023 Negatu DA, Aragaw WW, Dartois V, Dick T.
europepmc +1 more source
Identification of Mycobacterium tuberculosis Resistance to Common Antibiotics: An Overview of Current Methods and Techniques [PDF]
Xue-Song Xiong,1,2,* Xue-Di Zhang,3,* Jia-Wei Yan,3 Ting-Ting Huang,1,2 Zhan-Zhong Liu,4 Zheng-Kang Li,5 Liang Wang,5 Fen Li1,2 1Department of Laboratory Medicine, The Affiliated Huai’an Hospital of Yangzhou University, Huai’an, Jiangsu Province,
Huang TT +7 more
core +1 more source
Tuberculosis in the European Region. [PDF]
Curr Trop Med Rep, 2023 Mencarini J +3 more
europepmc +1 more source
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. [PDF]
Antimicrob Agents Chemother, 2023 Negatu DA +4 more
europepmc +1 more source
Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic. [PDF]
Transl Clin PharmacolKoh J +4 more
europepmc +1 more source
New drugs for the management of tuberculosis. [PDF]
Curr Opin Infect DisCross GB.
europepmc +1 more source
Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies. [PDF]
J Clin Tuberc Other Mycobact DisTimboe K, Jackson JB, Becker GL.
europepmc +1 more source
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. [PDF]
Med Res Rev, 2021 Egorova A +3 more
europepmc +1 more source